Amid ongoing patent litigation, the FDA has approved Amgen’s Amjevita: the first US biosimilar version of AbbVie’s top selling rheumatoid arthritis biologic Humira.
Fixed-bed, high cell density bioreactors and a naturally occurring attenuated viral strain will be used by Batavia Biosciences in an attempt to produce an affordable rotavirus vaccine.
Abec has completed work on Regeneron’s biologics facility in Ireland just 28 months after it was hired to kit out the repurposed computer plant.
Bluebird Bio’s sickle cell disease gene therapy LentiGlobin has been accepted into the EMA’s priority review programme, PRIME.
Government efforts to encourage local drug production have “activated” the Russian biomanufacturing technology market according to GE Healthcare.
WuXi has responded to global demand for perfusion technologies by opening a commercial scale manufacturing site in China with two 1,000L disposable bioreactors.